These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15171451)

  • 1. [Renal protective action of T-, L-, and N-type Ca channel blockers].
    Hayashi K
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():654-61. PubMed ID: 15171451
    [No Abstract]   [Full Text] [Related]  

  • 2. Ca2+ channel subtypes and pharmacology in the kidney.
    Hayashi K; Wakino S; Sugano N; Ozawa Y; Homma K; Saruta T
    Circ Res; 2007 Feb; 100(3):342-53. PubMed ID: 17307972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of L-type and mixed L- and T-type calcium channel blockers on kidney injury caused by deoxycorticosterone-salt hypertension in rats.
    Baylis C; Qiu C; Engels K
    Am J Kidney Dis; 2001 Dec; 38(6):1292-7. PubMed ID: 11728963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular effects of new calcium antagonists: is the principle of parcimony out of place?].
    Richard S; Virsolvy A; Fort A
    Ann Cardiol Angeiol (Paris); 2008 Jun; 57(3):166-73. PubMed ID: 18565491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Calcium antagonists: current and future applications based on new evidence. Renal protective action of calcium channel blockers].
    Kimura G
    Clin Calcium; 2010 Jan; 20(1):94-9. PubMed ID: 20048440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New calcium channel blockers for the treatment of hypertension].
    Tamargo J
    Hipertens Riesgo Vasc; 2017; 34 Suppl 2():5-8. PubMed ID: 29908667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scaffold-based design and synthesis of potent N-type calcium channel blockers.
    Zamponi GW; Feng ZP; Zhang L; Pajouhesh H; Ding Y; Belardetti F; Pajouhesh H; Dolphin D; Mitscher LA; Snutch TP
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6467-72. PubMed ID: 19815411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional and pharmacological consequences of the distribution of voltage-gated calcium channels in the renal blood vessels.
    Hansen PB
    Acta Physiol (Oxf); 2013 Apr; 207(4):690-9. PubMed ID: 23351056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological activity of 3,4-dihydroquinazolines for selective T-type Ca2+ channel blockers.
    Rhim H; Lee YS; Park SJ; Chung BY; Lee JY
    Bioorg Med Chem Lett; 2005 Jan; 15(2):283-6. PubMed ID: 15603940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-/N-type calcium channel blockers and proteinuria.
    Ando K
    Curr Hypertens Rev; 2013 Aug; 9(3):210-8. PubMed ID: 24479751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus.
    Masuda T; Ogura MN; Moriya T; Takahira N; Matsumoto T; Kutsuna T; Hara M; Aiba N; Noda C; Izumi T
    Cardiovasc Ther; 2011 Feb; 29(1):46-53. PubMed ID: 20337636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-threshold L-type calcium channels in rat dopamine neurons.
    Durante P; Cardenas CG; Whittaker JA; Kitai ST; Scroggs RS
    J Neurophysiol; 2004 Mar; 91(3):1450-4. PubMed ID: 14645383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis.
    Ishimitsu T; Kameda T; Akashiba A; Takahashi T; Ohta S; Yoshii M; Minami J; Ono H; Numabe A; Matsuoka H
    Hypertens Res; 2007 Jul; 30(7):621-6. PubMed ID: 17785930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
    Akizuki O; Inayoshi A; Kitayama T; Yao K; Shirakura S; Sasaki K; Kusaka H; Matsubara M
    Eur J Pharmacol; 2008 Apr; 584(2-3):424-34. PubMed ID: 18331727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and SAR studies of a novel series of T-type calcium channel blockers.
    Park SJ; Park SJ; Lee MJ; Rhim H; Kim Y; Lee JH; Chung BY; Lee JY
    Bioorg Med Chem; 2006 May; 14(10):3502-11. PubMed ID: 16434203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetylcholine release at neuromuscular junctions of adult tottering mice is controlled by N-(cav2.2) and R-type (cav2.3) but not L-type (cav1.2) Ca2+ channels.
    Pardo NE; Hajela RK; Atchison WD
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1009-20. PubMed ID: 16982704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-type Ca channel blockers in patients with chronic kidney disease in clinical practice.
    Abe M; Okada K; Soma M
    Curr Hypertens Rev; 2013 Aug; 9(3):202-9. PubMed ID: 24479749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. State-dependent verapamil block of the cloned human Ca(v)3.1 T-type Ca(2+) channel.
    Freeze BS; McNulty MM; Hanck DA
    Mol Pharmacol; 2006 Aug; 70(2):718-26. PubMed ID: 16699084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling.
    Moore KH; Clemmer JS
    Am J Physiol Renal Physiol; 2021 Oct; 321(4):F548-F557. PubMed ID: 34486399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers.
    Ku IW; Cho S; Doddareddy MR; Jang MS; Keum G; Lee JH; Chung BY; Kim Y; Rhim H; Kang SB
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5244-8. PubMed ID: 16876404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.